Clinical trial
A Multi-centre, Prospective, Non-interventional Study Investigating the Effectiveness of Once-weekly Subcutaneous Semaglutide in a Real World Adult Population With Type 2 Diabetes
NCT03876015 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-centre, Prospective, Non-interventional Study Investigating the Effectiveness of Once-weekly Subcutaneous Semaglutide in a Real World Adult Population With Type 2 Diabetes
- Lead sponsor
- Novo Nordisk A/S
- Phase
- Observational
- Overall status
- Completed
- Start date
- May 1, 2019
- Completion date
- August 12, 2020
- Enrollment
- 215 (actual)
- Sites
- 31
Conditions
As the registry lists them; a condition with its own page is linked.